EGFR and neoplasm: In total, 49 patients (43.0%) were both tumor-tissue and plasma cfDNA EGFR M+; 31 patients (27.2%) were tumor-tissue EGFR M+ but plasma cfDNA EGFR M-; 3 patients (2.6%) were tumor-tissue EGFR M- but plasma cfDNA EGFR M+; and 31 patients (27.2%) were both tumor-tissue and plasma cfDNA EGFR M-.